Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,452.60 35.07 0.24%
TOPIX 1,167.40 0.81 0.07%
HANG SENG 22,760.24 64.23 0.28%

InnoPharma Inc. Announces Launch of Generic Cidofovir Injection in the United States



InnoPharma Inc. Announces Launch of Generic Cidofovir Injection in the United
States

PISCATAWAY, NJ, March 8, 2013 (GLOBE NEWSWIRE) -- InnoPharma, Inc. today
announced the launch of cidofovir injection (generic equivalent of Vistide®)
in 5mL single-use vials.  InnoPharma developed the generic formulation of
cidofovir, which will be marketed in the United States by Mylan, Inc. (NASDAQ:
MYL).

Cidofovir injection is indicated for the treatment of cytomegalovirus (CMV)
retinitis in patients with acquired immunodeficiency syndrome (AIDS).  For
more information regarding this product, including its black box warning,
please refer to the Mylan website at www.mylan.com.

About InnoPharma, Inc.

InnoPharma is a sterile product development company, focused on developing
complex generic and innovative specialty pharmaceutical products in injectable
and ophthalmic dosage forms. The Company has a broad portfolio of products
under development, with formulations including solutions, suspension,
lyophilized, emulsions, liposomes, micelles and lipid complexes. InnoPharma's
pipeline includes small molecules with solubility and stability challenges, as
well as difficult to produce and characterize polypeptides and carbohydrates.
The Company has a comprehensive infrastructure for the development of its
products in its state of the art R&D facilities in New Jersey, with the
capability to handle potent and cytotoxic molecules. More information can be
found at www.innopharmainc.com.

                                     ###

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, some of which are outside management's control, which may
cause results to differ materially from those set forth in the statements. The
forward-looking statements may include statements regarding product
development, product potential, or financial performance.  These risks, trends
and uncertainties are in some instances beyond our control. Words such as
"anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and
other similar expressions identify forward-looking statements, although not
all forward-looking statements contain these identifying words. InnoPharma,
Inc. undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or
otherwise.

CONTACT: John C. Deighan, CFO
         InnoPharma, Inc.
         (732) 885-2939
         jdeighan@innopharmainc.com

InnoPharma Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement